국가: 영국
언어: 영어
출처: MHRA (Medicines & Healthcare Products Regulatory Agency)
Meptazinol hydrochloride
Almirall Ltd
N02AX05
Meptazinol hydrochloride
100mg/1ml
Solution for injection
Intramuscular; Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 04070200; GTIN: 5021840006606
1 PACKAGE LEAFLET: INFORMATION FOR THE USER MEPTID 100 MG/ML SOLUTION FOR INJECTION Meptazinol READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET : 1. What Meptid Injection is and what it is used for 2. Before Meptid Injection is used 3. How Meptid Injection is used 4. Possible side effects 5. How to store Meptid Injection 6. Further information 1. WHAT MEPTID INJECTION IS AND WHAT IT IS USED FOR The name of this medicine is Meptid 100 mg/ml Solution for Injection but will be referred to as Meptid Injection throughout the remainder of the leaflet. Meptid Injection belongs to a group of medicines known as opioid analgesics, which are used to relieve pain. It contains meptazinol as the active ingredient. Meptid Injection is used to treat moderate to severe pain, including post-operative pain, pain during childbirth and the pain of renal colic. 2. BEFORE MEPTID INJECTION IS USED DO NOT USE MEPTID INJECTION IF YOU - are allergic (hypersensitive) to Meptazinol or any of the other ingredients of Meptid Injection _(see _ _Section 6 ‘Further information’)_ - have any alcohol-related problems - have or you are at risk of getting the condition known as paralytic ileus - have a head injury, or build-up of pressure in the head (raised intracranial pressure) - are having problems breathing - are suffering from a tumour of the adrenal gland (phaeochromocytoma) - are having an asthma attack - are taking medicines known as monoamine-oxidase inhibitors(MAOIs) or have stopped taking MAOIs less than 14 days ago TAKE SPECIAL CARE WITH MEPTID INJECTION IF YOU - have any liver or kidney problems - 전체 문서 읽기
OBJECT 1 MEPTID INJECTIONS Summary of Product Characteristics Updated 24-Jun-2015 | Almirall Limited 1. Name of the medicinal product Meptid 100mg/ml Solution for injection 2. Qualitative and quantitative composition Each 1 ml of solution contains 100mg of meptazinol (as hydrochloride). For a full list of excipients, see section 6.1. 3. Pharmaceutical form Solution for injection. Clear colourless solution free from particulate matter. 4. Clinical particulars 4.1 Therapeutic indications For the treatment of moderate to severe pain, including post-operative pain, obstetric pain and the pain of renal colic. 4.2 Posology and method of administration Adults Intramuscular dosage: 75-100mgMeptid. The injection may be repeated 2-4 hourly as required. For obstetric pain a dose of 100-150mg should be used according to weight. This dose should approximate 2mg/kg. Intravenous dosage: 50-100mg Meptid by slow intravenous injection. The injection may be repeated 2-4 hourly as required. If vomiting occurs, a suitable antiemetic should be given. Epidural/intrathecal use: This formulation is not suitable for these routes. Elderly The adult dosage schedule can be used in the elderly. Children Meptid injection has not been evaluated for use in children. 4.3 Contraindications Patients with the following conditions: - known hypersensitivity to the active ingredient or to any of the excipients - acute alcoholism and where there is a risk of paralytic ileus - raised intracranial pressure or head injury (in addition to interfering with respiration, affect pupillary responses vital for neurological assessment) - phaeochromocytoma (risk of pressor response to histamine release) - acute respiratory depression - during an asthma attack - patients on monoamine-oxidase inhibitors (MAOIs) and for 14 days after discontinuing an MAOI. (see section 4.5) 4.4 Special warnings and precautions for use Caution should be exercised in patients whose respiratory system is already compromised. Patients with moderate to severe renal impairment should be giv 전체 문서 읽기